Sana Biotechnology, Inc. (SANA)
NASDAQ (NGS) NASDAQ (NGS) Primary 
Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Evercore 8th Annual Healthcare Conference Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
Sana Biotechnology, Inc. (SANA) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
All You Need to Know About Sana (SANA) Rating Upgrade to Buy
Sana (SANA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Sana Biotechnology: Scope Goes Beyond HIP-Modified Pancreatic Islet Cells For T1D
Sana Biotechnology, Inc. remains a Strong Buy, driven by progress in HIP-modified cell therapies for Type 1 Diabetes and B-cell-mediated disorders. Sana Biotechnology's HIP-modified islet cell therapy showed a 6-month insulin response without needing immunosuppression in one T1D patient, supporting a paradigm shift in treatment. Upcoming 2025 data readouts from phase 1 GLEAM (SC291, autoimmune disorders) and VIVID (SC262, B-cell malignancies) trials are key catalysts for Sana Biotechnology.
Sana Biotechnology: A Big Winner In Waiting? Maybe, But It Won't Happen Overnight
Sana Biotechnology, Inc. surged after hedge fund manager Eric Jackson called it a potential "100-bagger" due to its pioneering diabetes cell therapy. Sana Biotechnology's breakthrough islet cell therapy, using proprietary hypoimmune technology, enabled insulin production in a type 1 diabetes patient without immunosuppression. Significant challenges remain: scalable cell manufacturing, safe and scalable administration, and massive funding needs before commercial viability is achieved.
Sana Biotechnology, Inc. (SANA) Presents at Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Sana Biotechnology, Inc. (NASDAQ:SANA ) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 8:00 AM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Yanan Zhu - Wells Fargo Securities, LLC, Research Division Presentation Yanan Zhu Senior Equity Analyst Great. Thanks, everyone, for being here.
Sana Biotechnology, Inc. (SANA) Presents At Citi's Biopharma Back To School Conference Transcript
Sana Biotechnology, Inc. (NASDAQ:SANA ) Citi's Biopharma Back to School Conference September 2, 2025 3:15 PM EDT Company Participants Steven Harr - President, CEO & Director Conference Call Participants Samantha Semenkow - Citigroup Inc., Research Division Presentation Samantha Semenkow Vice President Thank you for being here. My name is Sam Semenkow, I'm one of the Biotech analysts here at Citi.
Sana Biotechnology: Fundraising Triggers Major Sell-Off, I'm Still Intrigued
Sana's allogeneic HIP technology achieved a first in T1D, showing insulin production and immune evasion without immunosuppression, but scalability remains unproven. Despite promising early data, Sana faces significant risks: cash burn, a small recent raise, key executive departures, and a long path to commercialization. Management's experience and the disruptive potential of HIP technology support my continued Buy rating, but I advise caution due to high risk and lack of near-term catalysts.
Sana: HIP-Modified Islet Cells To Possibly Change Scope Of Type 1 Diabetes Treatment
Data from phase 1 studies using SC291 to treat patients with B-cell mediated autoimmune disorders and SC262 for patients with relapsed/refractory B-cell malignancies expected in 2025. First-in-human study using UP421 as a HIP-modified primary islet cell therapy to treat patients with Type 1 Diabetes established increase circulating C-peptide biomarker and without need of immunosuppressive therapy. An IND filing to initiate a phase 1 study using SC451 for the treatment of patients with Type 1 Diabetes, expected in 2026.
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421
SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which also received FDA Fast Track for r/r SLE, extrarenal lupus, and lupus nephritis. However, UP421 might be the most promising. It restored insulin production in a type 1 diabetes patient.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Sana Biotechnology, Inc. - SANA
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Pomerantz LLP is investigating claims on behalf of investors of Sana Biotechnology, Inc. ("Sana" or the "Company") (NASDAQ:SANA). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SANA Stock Surges 152% in a Week on Upbeat Initial Diabetes Study Data
Sana stock soars in a week following positive initial data from a first-in-human study of investigational cell therapy, UP421, in diabetes patients.
